In a clinical trial a heart stent manufactured by Boston Scientific Corp. (NYSE:BSX) has been proven to be as effective as one already on the market, which was developed by Abbott Laboratories Inc (NYSE:ABT), a major competitor of BSX.
when compared with the older Promus, which is sold by Abbott under the brand name Xience, study of 1,750 patients from around the globe found the new drug-eluting Promus Element stent was comparable in results.
Conclusions were there were no measurable differences between Promus Element and Xience in regard to effectiveness and safety.
Boston Scientific was trading at $7.12, falling $0.18, or 2.47 percent, as of 12:41 PM EDT. Abbott Laboratories Inc was trading at $50.31, gaining $0.94, or 1.90 percent.
No comments:
Post a Comment